# Auto Review: results.txt

Generated: 2026-04-28 14:57
Reviewer: Qwen2.5-32B-Instruct-AWQ (auto_review.py)

## Summary

- **Samples**: 8
- **Clean**: 0/8
- **P0** (hallucination): 0
- **P1** (major error): 26
- **P2** (minor issue): 43

### Critical Issues

- **ROW 1** [P1]: Missing current medications.
- **ROW 1** [P1]: Does not specify the type of pancreatic cancer or the stage.
- **ROW 4** [P1]: Major error - current medications are missing.
- **ROW 4** [P1]: Major error - supportive medications listed are incomplete.
- **ROW 4** [P1]: The reason for the visit is incomplete. It should specify that the visit was for follow-up of disease status and symptom management.
- **ROW 4** [P1]: This statement is too vague and doesn't provide enough detail for the patient to understand their situation.
- **ROW 15** [P1]: The sentence omits the specific term 'peritoneal metastases', which is important for patient understanding.
- **ROW 15** [P1]: This statement is incomplete; it should mention the resolving infection in the lungs.
- **ROW 15** [P1]: The sentence is confusing and uses medical jargon without explanation.
- **ROW 36** [P1]: The diagnosis is not accurately described as 'pancreatic cancer', but rather 'nonfunctioning pancreatic neuroendocrine tumor'.
- **ROW 36** [P1]: The exact reduced dose is missing.
- **ROW 36** [P1]: The exact reduced dose is missing.
- **ROW 40** [P1]: Major error - current medications are missing despite being listed in the note.
- **ROW 40** [P1]: Incomplete information. The exact dose increase for the fentanyl patch is missing.
- **ROW 43** [P1]: Major error - current medications are missing.
- **ROW 43** [P1]: The letter omits the specific type of pancreatic cancer and the term 'borderline resectable'.
- **ROW 43** [P1]: The letter does not mention the initial high levels and the context of the decline.
- **ROW 59** [P1]: Incorrect staging information.
- **ROW 59** [P1]: Missing current medications.
- **ROW 59** [P1]: Missing recent treatment changes.
- **ROW 59** [P1]: Missing supportive medications.
- **ROW 59** [P1]: Incorrect treatment goal.
- **ROW 59** [P1]: The letter omits important context about the specific nature of the cancer and its stage.
- **ROW 59** [P1]: The letter omits important information about the stability of the nodule and the absence of other concerning findings.
- **ROW 82** [P1]: Major error - current medications are missing from the extracted data.
- **ROW 82** [P1]: The sentence is unclear and contains medical jargon that may confuse the patient.

---

## ROW 1 — ⚠️ ISSUES

**Type**: Moderately differentiated pancreatic adenocarcinoma
**Stage**: Originally Stage III (based on markedly elevated CA-19-9 at baseline, highly con

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Reason_for_Visit.summary | Inaccurate number of chemotherapy cycles completed. | He is now s/p 3 cycles of treatment. |
| P2 | Cancer_Diagnosis.Stage_of_Cancer | Stage of cancer not explicitly stated as 'III'. | Not explicitly stated in the note. |
| P2 | Lab_Results.lab_summary | Incorrect value for CA 19-9. | Cancer Antigen 19-9 6,105 (H) |
| P1 | Current_Medications.current_meds | Missing current medications. | baclofen, calcium carbonate/vitamin D3, lidocaine-prilocaine, loperamide, lorazepam, ondansetron, pr |
| P2 | Treatment_Changes.recent_changes | Missing recent changes in treatment. | No recent changes mentioned. |
| P2 | Treatment_Goals.goals_of_treatment | Goals of treatment not clearly defined as curative or palliative. | Curative intent suggested but not explicitly stated. |
| P2 | Medication_Plan.medication_plan | Incorrect number of cycles. | The patient will continue with the next cycle of treatment today (#5) |
| P2 | follow_up_next_visit.Next clinic visit | Inaccurate next visit details. | Plan to re-image after 4 more cycles for formal tumor re-evaluation. |

*Extraction summary*: Most fields are accurate, but there are minor inaccuracies and omissions regarding the number of chemotherapy cycles, current medications, and treatment goals.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Does not specify the type of pancreatic cancer or the stage. | You came in for a follow-up visit regarding your pancreatic cancer treatment. |
| P2 | Use of 'precipitous' is not at an 8th-grade reading level. | Additionally, there has been a precipitous drop in the CA-19-9 measurement, from |
| P2 | Medical terms like 'ondansetron' and 'prochlorperazine' are not explained. | Supportive medications such as loperamide, ondansetron, and prochlorperazine are |
| P2 | Use of 'up-front' and 'drive down' might be confusing. | Consider a period of up-front chemotherapy for up to 4-6 months, aiming to drive |

*Letter summary*: The letter needs clarification on the type and stage of cancer and simplification of medical terms and complex phrases to improve readability.

---

## ROW 4 — ⚠️ ISSUES

**Type**: Metastatic pancreatic ductal adenocarcinoma
**Stage**: Stage IV (metastatic to liver and peritoneum)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P1 | Current_Medications | Major error - current medications are missing. | Medication Instructions section lists several current medications. |
| P1 | Treatment_Changes | Major error - supportive medications listed are incomplete. | Supportive medications include acetaminophen, apixaban, bisacodyl, dexAMETHasone, fentaNYL, HYDROmor |
| P2 | follow_up_next_visit | Minor issue - next visit is not specified but should be implied. | Mr. [REDACTED] will take some time to decide whether he wishes to pursue further salvage rx vs a pur |

*Extraction summary*: Major errors in current medications and supportive medications listing. Minor issue with unspecified next visit.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | The reason for the visit is incomplete. It should specify that the visit was for follow-up of disease status and symptom management. | You came in for a follow-up visit regarding your pancreatic cancer treatment. |
| P1 | This statement is too vague and doesn't provide enough detail for the patient to understand their situation. | Your cancer is showing stable disease with some signs of progression. |
| P2 | Medical jargon 'hepatic segment V/VIII lesion' and 'pancreatic tail mass' are not explained. | Imaging shows stable hepatic segment V/VIII lesion and decreased size of the pan |
| P2 | Terms 'ascites', 'peritoneal implants', and 'peritoneal carcinomatosis' are not explained. | However, there is slightly worse large volume ascites and similar peritoneal imp |
| P2 | The term 'salvage treatment' and 'gemcitabine-based regimen' are not explained. | You will take some time to decide whether you wish to pursue further salvage tre |

*Letter summary*: The letter contains some inaccuracies and lacks sufficient detail for patient understanding. Some medical terms are not explained, affecting readability.

---

## ROW 15 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: Originally Stage IIB, now metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Cancer_Diagnosis.Stage_of_Cancer | The stage is incorrectly specified as 'Originally Stage IIB, now metastatic (Stage IV)' when the note does not provide an original stage. | This is a very pleasant 35-year-old Hispanic male who was diagnosed in October 2015 with metastatic  |
| P2 | Treatment_Changes.recent_changes | The field should include the specific medication name instead of using '[REDACTED]' multiple times. | We will resume [REDACTED]. He responded initially quite well to [REDACTED] but because of his residu |
| P2 | Imaging_Plan.imaging_plan | The imaging plan should specify 'CT Chest with Contrast' rather than just 'CT Chest'. | CT Chest With Contrast |

*Extraction summary*: Most fields are clean, but there are minor issues with the cancer staging, treatment details, and imaging plan specification.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | The sentence omits the specific term 'peritoneal metastases', which is important for patient understanding. | There has been a progression of your cancer, with new growths found in the linin |
| P1 | This statement is incomplete; it should mention the resolving infection in the lungs. | However, there is no sign of cancer spread in your lungs. |
| P1 | The sentence is confusing and uses medical jargon without explanation. | We will resume a medication. He responded initially quite well to a medication b |
| P2 | The sentence is clear but could be more specific about the timing. | A CT scan of your chest is planned to monitor your condition. |

*Letter summary*: The letter has some major omissions and confusing statements that could affect patient understanding. It needs clarification and simplification.

---

## ROW 36 — ⚠️ ISSUES

**Type**: Nonfunctioning pancreatic neuroendocrine tumor
**Stage**: Metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Lab_Results | Incomplete information. Note mentions recent labs but does not provide specific details. | Most recent labs notable for the following: |
| P2 | Current_Medications | Incomplete information. Note lists multiple medications but only 'everolimus' is mentioned. | cholecalciferol, vitamin D3, everolimus, LACTOBACILLUS RHAMNOSUS GG, lansoprazole, LIPASE/PROTEASE/A |
| P2 | Treatment_Changes | Incomplete information. Note mentions holding everolimus during partial SBO but does not specify the duration. | Everolimus held during that period of time, resumed two weeks ago. |
| P2 | Treatment_Goals | Inaccurate classification. Note suggests palliative care but does not explicitly state it. | We discussed the following issues and plan: |
| P2 | Medication_Plan | Incomplete information. Note mentions starting non-insulin pharmacologic treatment in the future but does not specify what it is. | discussed potential plan to start non-insulin pharmacologic rx in the future. |
| P2 | follow_up_next_visit | Incomplete information. Note specifies imaging every 6 months but does not mention the next clinic visit date. | in-person: 6 month intervals for imaging |

*Extraction summary*: Most fields are accurate, but there are minor omissions and incomplete information in several fields.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | The diagnosis is not accurately described as 'pancreatic cancer', but rather 'nonfunctioning pancreatic neuroendocrine tumor'. | You came in for a follow-up visit regarding your pancreatic cancer treatment. |
| P1 | The exact reduced dose is missing. | Your dose of everolimus was reduced from 10 to because of some side effects. You |
| P1 | The exact reduced dose is missing. | You will continue taking everolimus at the reduced dose of . |
| P2 | Medical jargon 'blood tests' should be explained. | You should watch for any signs of bowel problems and continue having regular blo |

*Letter summary*: The letter contains major omissions and inaccuracies that could affect patient understanding, and minor readability issues.

---

## ROW 40 — ⚠️ ISSUES

**Type**: Metastatic adenocarcinoma of the pancreas
**Stage**: 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P1 | Current_Medications | Major error - current medications are missing despite being listed in the note. | The note lists several current medications including fentanyl, insulin, levothyroxine, metformin, mo |

*Extraction summary*: One major error identified in the Current_Medications field. All other fields are clean.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | Incomplete information. The exact dose increase for the fentanyl patch is missing. | We plan to increase the dose of your fentanyl patch to and added Reglan and when |
| P2 | Medical jargon 'fine-needle aspiration' may be confusing. | You have a mass in the pancreas and liver lesions. Fine-needle aspiration of one |
| P2 | Unexplained medical term 'CA 19-9'. | Your CA 19-9 level on October 05 was 17,035. |

*Letter summary*: The letter contains some incomplete information and uses some medical jargon that might confuse the patient.

---

## ROW 43 — ⚠️ ISSUES

**Type**: Pancreatic adenocarcinoma
**Stage**: Borderline resectable pancreatic adenocarcinoma due to <180 degrees of vascular 

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P1 | Current_Medications | Major error - current medications are missing. | clopidogrel (PLAVIX) 75 mg tablet, docusate sodium (COLACE) 100 mg capsule, empagliflozin (JARDIANCE |
| P2 | Treatment_Changes | Minor issue - incomplete information about supportive medications. | Continue compazine on days June 28, then switch to zofran day 3 in the afternoon for 5 or 7 days. Ca |
| P2 | Treatment_Goals | Minor issue - unclear if 'curative' is the correct classification given the context of neoadjuvant chemotherapy. | Patient was recommended to undergo neoadjuvant chemotherapy. |
| P2 | Lab_Plan | Minor issue - incomplete information about monitoring schedule. | Continue to monitor [REDACTED] July 04 [REDACTED] 4 weeks. |
| P2 | Imaging_Plan | Minor issue - incomplete information about imaging schedule. | plan for CT CAP and visits with Dr. [REDACTED] and Dr. [REDACTED] after cycle 10. |

*Extraction summary*: Several fields contain major errors or minor omissions, impacting the completeness and accuracy of the extracted data.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | The letter omits the specific type of pancreatic cancer and the term 'borderline resectable'. | You came in for a follow-up visit regarding your pancreatic cancer treatment. |
| P1 | The letter does not mention the initial high levels and the context of the decline. | Your CA 19-9 levels, a tumor marker, have fluctuated but are slowly declining. |
| P2 | The term 'stable disease' might be confusing. | A CT scan on 11/19/19 showed stable disease. |
| P2 | The terms 'Oxaliplatin', 'Irinotecan', and 'bolus 5FU' are medical jargon. | Your chemotherapy doses were adjusted. Oxaliplatin and Irinotecan were reduced b |
| P2 | The terms 'Compazine' and 'Zofran' are brand names which may not be familiar to the patient. | You will continue to take Compazine and Zofran for nausea. |
| P2 | The term 'tenth cycle' might be confusing. | A CT scan is planned after your tenth cycle of treatment. |

*Letter summary*: The letter contains some omissions and uses some medical jargon that could confuse the patient.

---

## ROW 59 — ⚠️ ISSUES

**Type**: Adenocarcinoma of the pancreas, well to moderately differentiated
**Stage**: Originally Stage IIB, now metastatic (Stage IV)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P2 | Reason_for_Visit.summary | Inaccurate summary of purpose of visit. | Purpose of this visit is surveillance. |
| P1 | Cancer_Diagnosis.Stage_of_Cancer | Incorrect staging information. | Originally Stage IIB, now metastatic (Stage IV) |
| P1 | Current_Medications.current_meds | Missing current medications. | List of medications provided in the note. |
| P1 | Treatment_Changes.recent_changes | Missing recent treatment changes. | No recent changes mentioned. |
| P1 | Treatment_Changes.supportive_meds | Missing supportive medications. | Supportive medications listed in the note. |
| P1 | Treatment_Goals.goals_of_treatment | Incorrect treatment goal. | adjuvant |
| P2 | Imaging_Plan.imaging_plan | Incomplete imaging plan. | CT Chest |
| P2 | follow_up_next_visit.Next clinic visit | Inaccurate next visit details. | in-person: 6 months for surveillance |

*Extraction summary*: Several fields contain major errors or omissions, while others are incomplete or inaccurate.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | The letter omits important context about the specific nature of the cancer and its stage. | You came in for a follow-up visit regarding your pancreatic cancer treatment. |
| P1 | The letter omits important information about the stability of the nodule and the absence of other concerning findings. | There is no evidence of recurrent or metastatic disease within the abdomen and p |
| P2 | Medical jargon 'groundglass nodule' is not explained. | A 6mm groundglass nodule in the left upper lobe of the lung remains unchanged si |
| P2 | The term 'surveillance' may not be clear to the patient. | You will continue on surveillance. Your next visit is scheduled for 6 months fro |

*Letter summary*: The letter needs to include more context about the cancer and its treatment, and clarify medical terms for better patient understanding.

---

## ROW 82 — ⚠️ ISSUES

**Type**: Pancreatic adenocarcinoma
**Stage**: Stage IV (metastatic to liver and lung)

### Extraction

| Severity | Field | Issue | Note Evidence |
|----------|-------|-------|---------------|
| P1 | Current_Medications | Major error - current medications are missing from the extracted data. | Medications the patient states to be taking prior to today's encounter: fentaNYL (DURAGESIC) 25 mcg/ |
| P2 | Treatment_Changes | Minor issue - the list of supportive medications is incomplete. | Supportive medications include lidocaine-prilocaine (EMLA) 2.5-2.5% cream, ondansetron (ZOFRAN) 8 mg |
| P2 | follow_up_next_visit | Minor issue - the exact timing of the next clinic visit is not specified, but it should be inferred from the treatment plan. | he will obtain 4 cycles of chemotherapy followed by interval cross sectional imaging and CA 19-9 to  |

*Extraction summary*: Major error in missing current medications, minor issues in incomplete supportive medications and unspecified next visit timing.

### Letter

| Severity | Issue | Sentence |
|----------|-------|----------|
| P1 | The sentence is unclear and contains medical jargon that may confuse the patient. | Initiation of a modified a chemotherapy regimenIRI regimen including oxaliplatin |
| P2 | The term 'CA 19-9 tests' might be confusing for an 8th-grade reader. | You will receive 4 cycles of chemotherapy followed by imaging and CA 19-9 tests  |

*Letter summary*: The letter needs clarification on the new treatment plan and simplification of medical terms to improve readability.

---

